Home

Cohance Lifesciences PE Ratio

Image

Cohance Lifesciences Ltd

NSE: COHANCE

PE

146

Last updated on: Jul 13, 2025

Key Highlights

  • The P/E Ratio of Cohance Lifesciences Ltd is 146 as of 13 Jul 9.00 AM .
  • The P/E Ratio of Cohance Lifesciences Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 years.
  • The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 1021 as of 11 Jul 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.1 to 40.1 in 5 years. This represents a CAGR of 13.70%.
  • The PE Ratio of Automobile industry is 14.5. The PE Ratio of Finance industry is 27.9. The PE Ratio of IT - Software industry is 27.0. The PE Ratio of Pharmaceuticals industry is 33.9. The PE Ratio of Retail industry is 109.6. The PE Ratio of Textiles industry is 24.5 in 2025.

Historical P/E Ratio of Cohance Lifesciences Ltd

No data available

Company Fundamentals for Cohance Lifesciences Ltd

Image

Cohance Lifesciences Ltd

NSE: COHANCE

Share Price

₹ 1021.9

26.40 (2.65%)

stock direction

Last updated on: Jul 11, 2025

Market Price of Cohance Lifesciences Ltd

1M

1Y

3Y

5Y

Monitoring Cohance Lifesciences Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
11 Jul 20251021.9
10 Jul 2025995.5
09 Jul 2025985.75
08 Jul 2025990.45
07 Jul 20251018.75
04 Jul 20251043.8
03 Jul 20251006.65
02 Jul 2025967.4
01 Jul 2025960.35
30 Jun 2025966.65

SWOT Analysis Of Cohance Lifesciences Ltd

Strength

2

che

Weakness

1

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Cohance Lifesciences Ltd

Asset Value vs Market Value of Cohance Lifesciences Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Cohance Lifesciences Ltd39094
Sun Pharmaceutical Industries Ltd401289
Divis Laboratories Ltd181397
Cipla Ltd119949
Torrent Pharmaceuticals Ltd112127
Mankind Pharma Ltd106401

PE Ratio of Cohance Lifesciences Ltd Explained

39094

Market cap

267

Earnings

146.0X

PE Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Cohance Lifesciences Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Cohance Lifesciences Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Cohance Lifesciences Ltd

No data available

* All values are in %

About Cohance Lifesciences Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

Cohance Lifesciences Ltd News Hub

Suven Pharmaceuticals consolidated net profit declines 49.61% in the June 2024 quarter

Net profit of Suven Pharmaceuticals declined 49.61% to Rs 60.77 crore in the quarter ended June 2024

Read more

09 Aug 24

Suven Pharmaceuticals to hold board meeting

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 August 2024.

Read more

06 Aug 24

Suven Pharmaceuticals appoints Vivek Sharma as new Executive Chairman

Suven Pharmaceuticals announced the appointment of Vivek Sharma as the new Executive Chairman, effec

Read more

19 Sept 24

Board of Suven Pharmaceuticals approves change in Executive Chairperson

The Board of Suven Pharmaceuticals at its meeting held on 19 September 2024 has taken on record the

Read more

19 Sept 24

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Cohance Lifesciences Ltd

What is the current PE Ratio of Cohance Lifesciences Ltd?

The Current PE Ratio of Cohance Lifesciences Ltd is 145.99 as on 13 Jul 2025.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 33.9 as on 13 Jul 2025.

What was the PE Ratio of Cohance Lifesciences Ltd last year?

The PE Ratio of Cohance Lifesciences Ltd was 29.25 last year, now the PE ratio is 145.99, showing a year-on-year growth of 399.1%.

What does the PE Ratio of Cohance Lifesciences Ltd indicate about its stock?

The PE Ratio of Cohance Lifesciences Ltd is 145.99. This ratio indicates that investors are willing to pay 145.99 times the earnings per share for each share of Cohance Lifesciences Ltd.

What is the PE Ratio Growth of Cohance Lifesciences Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Cohance Lifesciences Ltd grew by 399.1% whereas, the EPS ratio grew by -49.4.

How does the PE ratio of Cohance Lifesciences Ltd compare to industry peers?

The PE ratio of Cohance Lifesciences Ltd PE Ratio can indicate whether it is overvalued or undervalued compared to competitors in the same industry. A lower PE ratio may suggest an undervalued stock, while a higher PE ratio could indicate premium pricing.

Is a high PE ratio for Cohance Lifesciences Ltd PE Ratio good or bad?

A high PE ratio may indicate strong future growth expectations, but it can also suggest overvaluation. It is best to compare it with industry averages and historical trends of Cohance Lifesciences Ltd PE Ratio.

What factors influence the PE ratio of Cohance Lifesciences Ltd PE Ratio?

The PE ratio of Cohance Lifesciences Ltd PE Ratio is influenced by factors such as earnings growth, investor sentiment, macroeconomic conditions, and sector trends.

How often does the PE ratio of Cohance Lifesciences Ltd PE Ratio change?

The PE ratio changes as the share price or earnings of Cohance Lifesciences Ltd PE Ratio fluctuate, and it is updated whenever there is a significant movement in either of these factors.

Where can I find the latest PE ratio of Cohance Lifesciences Ltd PE Ratio?

You can check the latest PE ratio of Cohance Lifesciences Ltd PE Ratio on BlinkX Website above or any other stock market platforms, or at the company’s official website.

What is a good PE ratio for Cohance Lifesciences Ltd PE Ratio?

A "good" PE ratio depends on industry standards and market conditions. It is advisable to compare Cohance Lifesciences Ltd PE ratio with its historical average and competitors.

Can the PE ratio of Cohance Lifesciences Ltd PE Ratio predict future stock performance?

While the Cohance Lifesciences Ltd PE ratio is a useful indicator of valuation, it should be used alongside other financial metrics and market analysis to make informed investment decisions.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions